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Open access under CC BHuman immunodeﬁciency virus-1 (HIV-1) successfully escapes from host immune surveillance, vaccines
and antiretroviral agents. The available antiretroviral compounds can only control viremia, but it is
impossible to eliminate the virus from the organism, namely because HIV-1 provirus persists in the res-
ervoir cells from which the virus repeatedly disseminates into new cells. Current therapeutic approaches,
however, do not speciﬁcally address the stage of virus reactivation.
Heme has been demonstrated as very efﬁcient in inhibiting HIV-1 reverse transcription, while its deriv-
ative hemin ameliorated HIV-1 infection via induction of heme oxygenase-1. Normosang (heme arginate;
HA) is a human hemin-containing compound used to treat acute porphyria. In this work, we studied the
effects of HA in HIV-1-acutely infected T-cell lines, and in cell lines harboring either a complete HIV-1
provirus (ACH-2 cells) or an HIV-1 ‘‘mini-virus’’ (Jurkat clones expressing EGFP under control of HIV
LTR). We demonstrate that HA inhibited HIV-1 replication during the acute infection, which was accom-
panied by the inhibition of reverse transcription. On the other hand, HA alone stimulated the reactivation
of HIV-1 ‘‘mini-virus’’ and synergized with phorbol ester or TNF-a in the reactivation of HIV-1 provirus.
The stimulatory effects of HA were inhibited by N-acetyl cysteine, suggesting an increased redox stress
and activation of NF-jB. Further, HA induced expression of heme oxygenase-1 (HO-1) in ACH-2 cells,
while HO-1 was found expressed in untreated Jurkat clones. Inhibitor of HO-1 activity, tin protoporphyrin
IX, further increased HA-mediated reactivation of HIV-1 ‘‘mini-virus’’ in Jurkat clones, and this effect was
also inhibited by N-acetyl cysteine. The stimulatory effects of HA on HIV-1 reactivation thus seem to
involve HO-1 and generation of free radicals. Additionally, the effective concentrations of HA did neither
affect normal T-cell activation with PMA nor induce activation of the unstimulated cells.
In conclusion, HA appears to possess a combination of unique properties that could help to decrease the
pool of latently infected reservoir cells, while simultaneously inhibiting HIV-1 replication in newly
infected cells. Our results thus suggest a new direction to explore in treatment of HIV/AIDS disease.
 2011 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Overall, 2 million people die of AIDS every year. The causative
agent of this deadly disease, Human immunodeﬁciency virus-1
(HIV-1), is one of the most variable viruses. The high evolution rate
helps the virus to escape from host immune surveillance, vaccines
and antiretroviral agents. The available antiretroviral compounds
can only control viremia, and it is currently impossible to eliminate
the virus from the organism, namely because HIV-1 provirus per-
sists in the reservoir cells. During intercurrent infections, the pro-
virus is repeatedly reactivated and disseminated into new cells,
thus enlarging the pool of reservoir cells. Current therapeutic ap-
proaches consist of combinations of several drugs inhibiting vari-: +420 22496 8588.
Y-NC-ND license.ous steps in HIV-1 growth cycle, but these drugs reveal serious
side effects, and the virus often gains resistance to them (Mehellou
and De Clercq, 2010; Walmsley and Loutfy, 2002). Therefore, more
potent and/or less toxic therapeutic approaches effective against
HIV are intensively sought.
Pathogenesis of HIV/AIDS infection is known to include an in-
creased redox stress that is characterized by the increased produc-
tion of reactive oxygen and nitrogen species, decreased levels of
reduced glutathione (GSH) and GSH-dependent antioxidant mech-
anisms, as well as depletion of the main antioxidant enzymes, such
as glutathione peroxidase, thioredoxin or catalase (Pace and Leaf,
1995). The increased redox stress leads not only to the reactivation
of the latent HIV-1 provirus, but also to an increased apoptosis and
depletion of uninfected CD4+ cells (Pace and Leaf, 1995). The
activation of the host cell is accompanied by the activation of the
redox-sensitive transcription factor NF-jB (Lander et al., 1993;
Pantano et al., 2006) and its translocation to the nucleus (Greene,
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grated HIV-1 provirus and induces its replication (Nabel and Balti-
more, 1987; Pyo et al., 2008; Williams et al., 2007). The redox state
of the cell thus simultaneously affects both activation of NF-jB and
reactivation of the latent provirus.
Current therapeutic approaches focus primarily on the inhibi-
tion of HIV-encoded enzymes reverse transcriptase and protease;
fusion inhibitors and inhibitors of co-receptors or integrase are
also available (Mehellou and De Clercq, 2010). Due to a high muta-
tion rate of HIV-1 and development of resistance, adherence to
strict regimes consisting of administration of several drugs a day
that keep the replication rates of HIV-1 in check, and thus decrease
the possibility of the outgrow of the resistant clones, is an essential
part of the therapy. Non-adherence to the regime as well as other
factors then support an increased mutation rate and development
of resistance. Evidently, it is desirable to pharmacologically target
host cell factors that cannot mutate and gain resistance as fast as
the virus. One such a target would be NF-jB and/or the process
of reactivation of HIV-1 provirus. However, a focused approach try-
ing to affect the redox stress and reactivation of the provirus (out-
side of the use of vitamins and the effort to avoid common diseases
in general) is not generally included in the therapeutic approaches.
In vitro, heme (Fe2+, ferroprotoporphyrin IX) has been demon-
strated as very efﬁcient in inhibiting HIV-1 reverse transcription
(Argyris et al., 2001; Levere et al., 1991). Further, hemin (Fe3+, fer-
riprotoporphyrin IX) ameliorated HIV-1 infection in humanized
mice, and heme oxygenase-1 (HO-1) was suggested to be respon-
sible for the inhibitory effect (HO-1; Devadas and Dhawan,
2006). Normosang (heme arginate, HA; Orphan Europe) is a human
hemin-containing compound used to treat acute porphyria. It is
composed of hemin and L-arginine as an additive to increase solu-
bility and stability of the product (Siegesmund et al., 2010), and it
shows fewer side effects in hemostasis compared to Panhaematin
(Ovation Pharmaceuticals; Volin et al., 1988). However, there are
no reports on the effect of HA on HIV-1 growth and reactivation.
Hence, we attempted to study the effect of HA on HIV-1 replication
in acutely infected T-cell lines A3.01 and Jurkat, as well as its ef-
fects on the latent provirus reactivation in PMA-stimulated ACH-
2 cells harboring HIV-1 provirus and in A2 and H12 clones of Jurkat
cells latently infected with an HIV-1 ‘‘mini-virus’’ containing EGFP
under control of HIV-1 LTR. Here we demonstrate that HA inhibited
HIV-1 replication during the acute infection of T-cell lines, which
was accompanied by the inhibition of reverse transcription. On
the other hand, HA alone stimulated the reactivation of HIV-1
‘‘mini-virus’’ and in combination with PMA or other stimulatory
agents the reactivation of HIV-1 provirus, with the stimulatory ef-
fects involving reactive oxygen species and activity of HO-1. Addi-
tionally, heme arginate did not activate T-cells nor inhibit the
activation of T cells by PMA.2. Materials and methods
2.1. Chemicals
All the media and growth supplements were purchased from
Invitrogen Corporation (Carlsbad, CA) or PAA Laboratories GmbH
(Pasching, Austria). Heme arginate (Normosang) was purchased
from Orphan Europe (Paris, France), tin protoporphyrin IX (SnPP)
from Frontier Scientiﬁc (Logan, UT), TNF-a from Peprotech (Lon-
don, United Kingdom), and RETRO-TEK HIV-1 p24 Antigen ELISA
from ZeptoMetrix Corp. (Buffalo, NY). Other chemicals used were
purchased from Sigma unless otherwise speciﬁed.2.2. Cell lines
Human T-cell lines A3.01 and Jurkat (a clone with high expres-
sion of CD4), ACH-2 cells harboring an integrated HIV-1 provirus
(clone #4; Clouse et al., 1989), and A2 and H12 clones of Jurkat
cells latently infected with a ‘‘mini-virus’’ containing the HIV-1
LTR-Tat-IRES-EGFP-LTR (Blazkova et al., 2009; Jordan et al., 2003)
were grown in RPMI 1640 supplemented with 10% fetal bovine ser-
um, 2 mM glutamine, 12.5 mM Hepes, and antibiotics (penicillin
1  105 U/l, streptomycin 100 mg/l; 10% FBS-RPMI). The cells were
treated with increasing concentrations of HA (1.25 and 2.5 ll/ml of
HA correspond to 31.25 and 62.5 lg/ml of hemin or 48 and 96 lM
hemin, respectively). ACH-2, A2 and H12 cells were stimulated
with phorbol myristate acetate (PMA; ﬁnal concentration 0.5 ng/
ml was used throughout the experiments) to express HIV-1 or
EGFP, respectively. The cells were also treated with N-acetyl cys-
teine (ﬁnal concentration 5 and 10 mM), SnPP (ﬁnal concentration
6.25 lM), TNF-a (ﬁnal concentration 1 and 10 U/ml), PHA (ﬁnal
concentration 0.5 and 1 lg/ml).2.3. Viruses and infection
The stock of HIV-1 was prepared using a transient transfection
of Jurkat cells with pNL4–3 (Adachi et al., 1986). The culture super-
natant was collected at day 7 after transfection and virus titer was
estimated as 4.8  1010 TU/ml (transducing units/ml) based on lev-
els of p24 antigen determined by RETRO-TEK HIV-1 p24 antigen
ELISA according to the manufacturer’s protocol. For time course
experiments, 0.2  106 cells in 0.2 ml of 10% FBS-RPMI were in-
fected with 2 ll of the stock; after 4 h of adsorption of inoculum,
0.8 ml of 10% FBS-RPMI was added and supplemented with HA (ﬁ-
nal concentration 1.25 and 2.5 ll/ml). The cells were split 1:4 at
the indicated times after infection and the media was supple-
mented with HA to keep the ﬁnal concentrations as indicated.
The growth of HIV-1 was characterized by levels of p24 antigen
in culture supernatants. For detection of HIV-1 reverse transcripts,
virus stock was treated with RNAse-free DNase I (Sigma, Germany;
ﬁnal concentration 300 U/100 ll of virus stock) and incubated at
room temperature for 45 min to remove plasmid and cellular
DNA present in the inoculum. 0.5  106 A3.01 and Jurkat cells in
0.2 ml of 10% FBS-RPMI were infected with 100 ll of the DNase
I-treated virus stock, and after 4 h of adsorption of inoculum,
0.8 ml of 10% FBS-RPMI was added and supplemented with HA (ﬁ-
nal concentration 2.5 ll/ml) or Azidothymidine (AZT; ﬁnal concen-
tration 10 lM) as a control. Forty eight hours after infection, the
cells were collected in PBS, trypsinized and used for DNA isolation.2.4. PCR detection of HIV-1 reverse transcripts
Total cellular DNA was isolated using a modiﬁed method of
Miller’s salting-out procedure, without proteinase K and with addi-
tion of a chloroform extraction phase (Olerup and Zetterquist,
1992). Ethanol-precipitated DNA was dissolved in TE buffer and
quantiﬁed by measuring the absorbance at 260 nm using UV spec-
trophotometer BioPhotometer (Eppendorff AG, Germany). HIV-1
reverse transcripts were determined by PCR using primers speciﬁc
for LTR/gag (Schmidtmayerova et al., 1998) and for GAPDH (sense
50-TTC TGT CTT CCA CTC ACT CC-30, antisense 50-GTA TTC CCC CAG
GTT TAC ATG-30) in a 50 ll reaction volume containing 1 U of Taq
DNA polymerase (Top-Bio, Czech Republic), 1x PCR buffer (10 mM
Tris–HCl, pH 8.8; 50 mM KCl; 0.1% Triton X-100), 200 nM each pri-
mer, 200 lM dNTPs, MgCl2 (1 mM for LTR/gag; 0.75 mM for GAP-
DH) and sample DNA (1000 ng for LTR/gag; 200 ng for GAPDH.
PCR conditions: initial denaturation 94 C/4 min and 35 cycles of
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60 s, with ﬁnal extension 72 C/10 min. The PCR products were re-
solved using a 1.5% agarose gel electrophoresis in 1 TBE buffer
and 0.5 lg/ml ethidium bromide, and visualized under UV
transilluminator.2.5. Western blot analysis
Cells were collected and lysed in Laemmli reducing sample buf-
fer, boiled and analyzed by SDS–PAGE and western blotting as pre-
viously described (Harlow and Lane, 1988; Laemmli, 1970), using
chemiluminescence (West Femto, Thermo Fisher Scientiﬁc –
Pierce, Rockford, IL). For p24 antigen, the cell lysates were resolved
on a 14% SDS–PAGE and detected using a monoclonal antibody ND-
1 (dilution 1:500; Exbio, Prague, Czech Republic) and a peroxidase-
conjugated goat anti-mouse IgG (dilution 1:20,000; Sigma Co., St.
Louis, MO). EGFP was detected using a 12% SDS–PAGE, a rabbit
polyclonal antibody (dilution 1:1000; Exbio, Prague, Czech Repub-
lic) and a peroxidase-conjugated goat anti-rabbit IgG (dilution
1:20,000; MP Biomedicals – Cappel, Solon, OH), HO-1 was detected
using a 10% SDS–PAGE, a rabbit polyclonal antibody (dilution
1:20,000; Abcam, Cambridge, United Kingdom) and a peroxidase-
conjugated goat anti-rabbit IgG (dilution 1:20,000). b-Actin was
detected on a 10% gel, using either a goat polyclonal antibody
(dilution 1:200; Santa Cruz Biotechnology, Santa Cruz, CA) and a
peroxidase-conjugated donkey anti-goat IgG (dilution 1:20,000;
Jackson ImmunoResearch Laboratories, West Grove, PA) or using
a rabbit polyclonal antibody (dilution 1:7500; Abcam, Cambridge,
United Kingdom) and a peroxidase-conjugated goat anti-rabbit
IgG (dilution 1:20,000).2.6. Flow cytometry analysis
Flow cytometer Canto II (Becton Dickinson) equipped with 3 la-
sers emitting at 488, 405 and 633 nm, and with 8 detectors was
used. Flow cytometry measurements were performed using the
Diva 6 software (Becton Dickinson, Franklin Lakes, NJ). Subsequent
analyses of the ﬂow cytometric data were performed using Diva 6
and/or FlowJo (Tree Star, Inc., Ashland, OR).Fig. 1. Example of a ﬂow cytometric analysis. Gating of the cell populations in
dependence on their size and granularity. Cell populations in Regions 1 and 2 were
used for further analysis; the two regions contained live and apoptotic cells,
respectively. The samples were collected, incubated with individual ﬂuorescent
indicators as indicated, and analyzed using ﬂow cytometry and Diva 6 or FlowJo
software.At each time point, cells were collected, stained with a ﬂuoro-
chrome, and used for further analysis in the appropriate detecting
channel. Ten thousand cells were collected upon gating on a FSC-
A  SSC-A dot plot. The region used for further analysis contained
live cells, as well as their apoptotic counterparts (Fig. 1). Discrim-
ination of apoptotic cells was performed on a FSC-A  SSC-A dot
plot and/or using staining with Hoechst 33342 (Intergen; ﬁnal con-
centration 0.1 lg/ml; Kalbacova et al., 2002; Lizard et al., 1996)
and 7-AAD (ﬁnal concentration (1 lg/ml) followed by ﬂow cytom-
etry analysis in FL5 (detecting at 474–496 nm) and FL4 (detecting
at 750–810 nm), respectively. Percentage of apoptotic cells deter-
mined on a FSC-A  SSC-A dot plot correlated with the percentage
of apoptotic cells determined on a Hoechst 33342  7-AAD dot plot
(not shown). For assessment of cell viability of the infected cells
during the time course experiment, the cells were ﬁrst ﬁxed with
1% paraformaldehyde, and then analyzed as described above.
EGFP ﬂuorescence was characterized by a ﬂow cytometry anal-
ysis in FL1 (detecting at 515–545 nm). EGFP expression was as-
sessed as the arithmetic mean of green ﬂuorescence of green cell
population  percentage of all EGFP-positive cells. EGFP ﬂuores-
cence intensity was characterized by the median ﬂuorescence of
live green cells. Detection of CD69 expression was performed using
a mouse monoclonal antibody against human CD69 labeled with
Alexa Fluor-700 (dilution 1:50; Exbio, Prague, Czech Republic) fol-
lowed by ﬂow cytometry analysis in FL7 (detecting at 700–
720 nm).
2.7. Cytotoxicity assays and determination of CC50
Cytotoxicity of heme arginate was characterized by determina-
tion of induction of apoptosis using ﬂow cytometry (see above)
and by the effects on cell viability and growth using a protocol
adapted according to TOX-1 kit (Sigma Co., St. Louis, MO). Brieﬂy,
A3.01 and Jurkat cells were diluted with fresh culture medium
and 24 h later, they were plated in 24-well plates at a density
of 0.06  106/ml/well in culture medium containing increasing
concentrations of HA. In parallel, wells with culture medium
and HA were incubated to be used as individual blanks for each
particular concentration of HA. After 2 days of incubation, cell
growth and viability were characterized by activity of mitochon-
drial dehydrogenases using the MTT assay. The conversion of MTT
to formazan was determined photometrically at 540 nm after dis-
solving the product in the acidiﬁed isopropanol. The cytotoxic
concentration was expressed as CC50, the concentration of the
tested compound that reduced cell growth to 50% compared to
vehiculum-treated controls.
2.8. Statistical analysis
Results are presented as means ± SD (standard deviation).
Statistical differences between each group and control or between
two groups were determined using a two-sample two-tailed
Student’s t-test for either equal or unequal variances. Equality of
variances was tested with F-test.3. Results
3.1. Heme arginate inhibits HIV-1 growth during the acute infection of
cells with HIV-1
The overall effect of heme arginate (HA) was assessed during a
time course experiment characterizing the acute infection of T-cell
lines A3.01 and Jurkat with HIV-1. As demonstrated in Fig. 2A,
addition of HA strongly inhibited growth of HIV-1 characterized
by levels of p24 in culture supernatants in both cell lines. The
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Fig. 2. Heme arginate inhibits HIV-1 growth during acute infection. (A and B) 0.2  106/ml of A3.01 or Jurkat cells were infected or mock-infected with HIV-1 and grown in
24-well plates in the presence of indicated concentrations of heme arginate (HA). The concentrations 1.25 and 2.5 ll/ml of HA correspond to 31.25 and 62.5 lg/ml of hemin or
48 and 96 lM hemin, respectively. At indicated days after infection (p.i.), aliquots of culture supernatants and cells were collected for further analysis, the cells were split 1:4,
and supplemented with fresh medium and HA. (A) p24 antigen in culture supernatants determined by ELISA. (B) Apoptosis of the cells characterized by ﬂow cytometry of
cells ﬁxed with 1% paraformaldehyde. Graphs (A and B) represent mean of two experiments performed in duplicates ±SD (C) Cytotoxicity of heme arginate. 0.06  106/ml of
A3.01 and Jurkat cells were treated with increasing concentrations of HA. After 2 days of incubation, apoptosis and cytotoxicity were characterized using ﬂow cytometry and
the MTT assay, respectively. The results represent means of three (A3.01) or two experiments (Jurkat) performed in duplicates ±SD.
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experiments and on the estimated distribution volume of HA
in vivo. At day 4 p.i., both 2.5 and 1.25 ll/ml of HA decreased the
levels of p24 antigen in the culture supernatants to about half of
the levels of the untreated controls in both cell lines. At later time
points, the concentration of HA 2.5 ll/ml kept the levels of p24
antigen very low, close to the detection limit of the assay; the con-
centration of HA 1.25 ll/ml decreased the levels of the p24 antigen
signiﬁcantly also, with an increase in p24 antigen levels at days 10
and 13 p.i.
In an additional series of experiments, we determined the via-
bility of HIV-infected and mock-infected cells in the presence of
1.25 and 2.5 ll/ml of HA during the time course experiment. As
shown in Fig. 2B, cell viability determined by the analysis of a
FSC-A  SSC-A dot plot decreased only in HIV-infected, untreatedcells. In contrast, both HA-treated infected and mock-infected cells
revealed a viability comparable to untreated mock-infected cells
up to the 13 days p.i.
Finally, we characterized the effects of HA on T-cell viability,
growth, and cytotoxicity in actively dividing A3.01 and Jurkat cells
during a 48 h experiment, comparing ﬂow cytometry and the MTT
assay (Fig. 2C). Percentage of apoptotic cells was determined by
analysis of a FSC-A  SSC-A dot plot. The cells were also analyzed
after labeling with Hoechst 33342 and 7-AAD, yielding similar re-
sults (data not shown). It can be observed that the concentrations
of HA 1.25 and 2.5 ll/ml that inhibit HIV-1 growth do not induce
any increased apoptosis of A3.01 cells, while 2.5 ll/ml of HA in-
creased apoptosis of Jurkat cells somewhat. Cytotoxicity and
growth inhibitory properties of HA were characterized by activity
of mitochondrial dehydrogenases using the MTT assay. 1.25 ll/ml
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Fig. 4. HA potentiates PMA-stimulated reactivation of the HIV-1 provirus in ACH-2
cells. 0.5  106/ml of ACH-2 cells harboring an integrated HIV-1 provirus were pre-
treated with increasing concentrations of HA for 24 h, and then stimulated with
phorbol myristate acetate (PMA; ﬁnal concentration 0.5 ng/ml) in the presence of
HA. 24 h after stimulation, aliquots of culture supernatants and cells were collected
for further analysis. (A) Western blot analysis of p24 antigen in the cells. The cells
were lysed in Laemmli reducing sample buffer, and resolved by SDS–PAGE. Levels of
p24, p55 and b-actin were characterized by western blot analysis and chemilumi-
nescence, using a mouse monoclonal antibody ND-1 against p24 and a goat
polyclonal antibody against b-actin, respectively. Representative results of two
independent experiments. (B) p24 antigen in culture supernatants. Levels of p24
antigen were determined by ELISA. Graphs represent mean of two independent
experiments performed in duplicates ± SD.
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2.5 ll/ml of HA somewhat decreased it in both cell lines. Based on
ﬂow cytometry assays, CC50 was determined as 42 and 17 ll/ml of
HA (1612 and 636 lM hemin) in A3.01 and Jurkat cells, respec-
tively; based on MTT test, CC50 was determined as 10.7 and
6.4 ll/ml of HA (412 and 244 lM hemin) in A3.01 and Jurkat cells,
respectively.
3.2. Heme arginate inhibits reverse transcription of HIV-1
It has been previously published that heme inhibited activity of
reverse transcriptase (Argyris et al., 2001; Levere et al., 1991; Stau-
dinger et al., 1996). Therefore we also tested the effects of HA on
reverse transcription as presented in Fig. 3. The results of PCR per-
formed on DNA isolated at 48 h after infection using primers spe-
ciﬁc for HIV LTR/gag demonstrate the inhibitory effects of HA on
levels of reverse transcripts that were comparable to those of
AZT. On the other hand, levels of a house-keeping gene GAPDH
were found comparable in all samples.
3.3. Heme arginate potentiates PMA-stimulated reactivation of the
HIV-1 provirus in ACH-2 cells
In contrast to reverse transcription, the effect of heme or hemin
on reactivation of the HIV-1 provirus has not been previously stud-
ied. Therefore, we ﬁrst determined the effects of HA on the stimu-
lation of ACH-2 cells harboring an integrated HIV-1 provirus with
PMA. Unexpectedly, results presented in Fig. 4 indicated that HA
dose-dependently increased reactivation of the provirus in PMA-
stimulated ACH-2 cells. In western blot analysis of the cells
(Fig. 4A), levels of the p24 antigen as well as of p55, its precursor,
were increased at 24 h after induction with PMA in the presence of
HA. Similarly in ELISA analysis of culture supernatants, levels of the
p24 antigen that reﬂect the p24 antigen and virions released from
the cells (Fig. 4B) were increased at 24 h after induction, in depen-
dence on the levels of HA. On the hand, HA alone was not found to
stimulate reactivation of the HIV-1 provirus at any concentration
tested (data not shown).
3.4. Heme arginate reactivates the latent HIV-1 ‘‘mini-virus’’ in clones
of Jurkat cells
In order to conﬁrm the stimulatory effects of HA on the reacti-
vation of the latent provirus, we have used two clones of Jurkat
cells harboring HIV-1 ‘‘mini-virus’’ consisting of the HIV-1 LTR-
Tat-IRES-EGFP-LTR. The two clones were previously shown to dif-
ferentially express EGFP and to contain different DNA modiﬁca-
tions in the promoter region (Blazkova et al., 2009; Jordan et al.,
2003). In agreement with the results in ACH-2 cells, western blot
analysis of EGFP (Fig. 5A) revealed a stimulatory effect of HA on
EGFP expression in PMA-stimulated A2 and H12 Jurkat cells. The
effect of HA alone on EGFP expression was also stimulatory, albeit
weaker than that in combination with PMA. In both experiments,HIV-1 LTR/gag
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The effects of HA and PMA on the expression of EGFP were also
studied using ﬂow cytometry (Fig. 5B, Supplementary data
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Fig. 5. HA reactivates the latent HIV-1 ‘mini-virus’ and expression of EGFP. 0.5  106/ml (A) or 0.1  106/200 ll (B) of Jurkat cell clones A2 and H12 latently infected with a
‘‘mini-virus’’ containing the HIV-1 LTR-Tat-IRES-EGFP-LTR were pre-treated with increasing concentrations of HA for 24 h, and then stimulated with PMA (ﬁnal concentration
0.5 ng/ml) or mock-treated in the presence of HA. Twenty four hours after stimulation, the cells were collected and used for further analysis. (A) Western blot analysis of EGFP
in the cells. The cells were lysed in Laemmli reducing sample buffer, and resolved by SDS–PAGE. Levels of EGFP and b-actin were characterized by western blot analysis and
chemiluminescence, using a rabbit polyclonal antibody against EGFP and a goat polyclonal antibody against b-actin, respectively. Representative results of two independent
experiments. (B) Flow cytometric analysis of EGFP expression. The cells were analyzed by ﬂow cytometry in FL1. The graphs show a quantiﬁcation of EGFP expression
calculated as the arithmetic mean of green ﬂuorescence of green cell population  percentage of all EGFP-positive cells. ⁄Increase in EGFP expression is statistically signiﬁcant
when compared to HA 0 in each treatment (p < 0.05). , Increase in EGFP expression in the presence of PMA is statistically signiﬁcant when compared to the same
concentration of HA without PMA (p < 0.05).
P. Shankaran et al. / Antiviral Research 92 (2011) 434–446 439higher background expression of EGFP than A2 cells. Again, the in-
creased expression of EGFP inversely correlated with cell viability,
with a signiﬁcant increase of apoptosis at concentrations of HA
2.5 ll/ml and higher.
3.5. Heme arginate with PMA stimulate expression of heme-
oxygenase-1 in ACH-2 cells and the stimulatory effects on reactivation
of the HIV-1 provirus can be inhibited by N-acetyl cysteine
Heme and hemin are well-established inducers of heme oxy-
genase-1 (HO-1; Maines et al., 1986; Wu and Wang, 2005), the en-
zyme degrading heme into carbon monooxide, biliverdin and Fe2+
(Tenhunen et al., 1969). The release of Fe2+ would catalyze produc-
tion of the hydroxyl radical (Kruszewski, 2003), thus possibly lead-
ing to activation of the transcription factor NF-jB and reactivationof the HIV-1 provirus. Therefore, we have ﬁrst determined the
expression of HO-1 in ACH-2 cells. As demonstrated in Fig. 6A,
HA induced a dose-dependent increase in HO-1 levels in the pres-
ence of PMA, i.e. under the conditions leading to the reactivation of
HIV-1 provirus, while untreated cells revealed low background lev-
els of HO-1 that were not affected by PMA alone. Consequently, we
pretreated the cells with an anti-oxidative agent N-acetyl cysteine
(NAC), precursor of the reduced glutathione (GSH). As shown in
Fig. 6B, NAC decreased reactivation of the provirus in HA-pre-
treated, PMA-stimulated ACH-2 cells, as characterized by levels
of the p24 antigen in the cells using western blot analysis. Addi-
tionally, it can be observed that NAC also decreased expression of
the p24 antigen in cells treated with PMA only. On the other hand,
ELISA analysis of culture supernatants (Fig. 6C) revealed that pre-
treatment with NAC decreased the levels of p24 antigen released
PMA
0    1.25   2.5   5.0   7.5     0 HA
HO-1
β-actin
ACH-2 HA 48 h
PMA 24 h
NAC        - +     - - - +      - +                       
PMA        - - - - +      +      +     +             
HA        - - +     +      - - +      +              
p24
β-actin
ACH-2 HA 48 h
PMA 24 h
p2
4 
(p
g/
m
l)
0
N
A
C
H
A
H
A
+N
A
C
PM
A
PM
A
+N
A
C
H
A
+P
M
A
H
A
+P
M
A
+N
A
C
0
200
400
600
ACH-2 HA 48 h
PMA 24 h
A
B
C
Fig. 6. (A) HA with PMA stimulate expression of heme oxygenase-1 in ACH-2 cells.
0.5  106/ml of ACH-2 cells harboring an integrated HIV-1 provirus were pre-
treated with increasing concentrations of HA for 24 h, and then stimulated with
PMA (ﬁnal concentration 0.5 ng/ml) in the presence of HA. 24 h after stimulation,
the cells were collected, lysed in Laemmli reducing sample buffer, and resolved by
SDS–PAGE. Levels of HO-1 and b-actin were characterized by western blot analysis
and chemiluminescence, using a rabbit polyclonal antibody against HO-1 and a
rabbit polyclonal antibody against b-actin, respectively. (B) N-acetyl cysteine
prevents reactivation of the HIV-1 provirus. 0.5  106/ml of ACH-2 cells were pre-
treated with N-acetyl cysteine (NAC; ﬁnal concentration 5 mM) for 4 h, treated with
5 ll/ml of HA for 24 h, and then stimulated with PMA in the presence of HA and/or
NAC. Levels of p24 and b-actin were characterized by western blot analysis and
chemiluminescence, using a mouse monoclonal antibody ND-1 against p24 and a
rabbit polyclonal antibody against b-actin, respectively. (C) Levels of p24 antigen in
culture supernatants were determined by ELISA. Representative results of two
independent experiments ±SD.
440 P. Shankaran et al. / Antiviral Research 92 (2011) 434–446by PMA-stimulated ACH-2 cells, while it was not sufﬁcient to sig-
niﬁcantly decrease p24 release by HA-pretreated, PMA-stimulated
cells.3.6. Expression of heme-oxygenase-1 in clones of Jurkat cells and the
effects of tin protoporphyrin IX and N-acetyl cysteine
We have also studied the levels of HO-1 in A2 and H12 Jurkat
cells. In these cells, HO-1 was found expressed already in untreated
cells and the addition of either HA or HA and PMA did not increase
its levels (Fig. 7A and data not shown). On the contrary, increasingconcentrations of HA led to a decrease of HO-1 levels in A2 and
H12 cells, in parallel with a cytotoxic effect of HA demonstrated
by decreasing levels of b-actin. Consequently, we explored the ef-
fect of NAC in these cells. Similarly to the effects observed in
ACH-2 cells, pretreatment with NAC decreased the levels of EGFP
in A2 and H12 cells treated with both HA and PMA, as well as in
cells treated with PMA only (Fig. 7B; expression of EGFP induced
by HA only could be observed in longer exposures). Finally, we
studied the effect of an inhibitor of HO-1, tin protoporphyrin IX
(SnPP; Devadas and Dhawan, 2006). SnPP strongly stimulated
expression of EGFP in cells treated with HA alone (Fig. 7C); it also
somewhat increased levels of EGFP in HA- and PMA-treated cells,
while it did not affect or somewhat decreased the levels of EGFP
in PMA-stimulated cells. On the other hand, SnPP alone did not
stimulate any expression of EGFP in untreated cells.
The effects of SnPP and NAC on the expression of EGFP were fur-
ther studied using ﬂow cytometry (Fig. 7D, Supplementary data
Table S2), providing amore quantitative assessment of EGFP expres-
sion. The results revealed similar tendencies as the western blot
analysis. Additionally, SnPP seemed to decrease basal expression
of EGFP in otherwise untreated A2 cells, while it did not affect it in
untreated H12 cells. On the other hand, NAC did not affect expres-
sion of EGFP in untreated A2 cells, while it decreased it in untreated
H12 cells. Also, NAC decreased expression of EGFP stimulated by all
the combinations of HA, SnPP and PMA, suggesting that these effects
were mediated by an increased redox stress. It should be also noted
that in contrast to A2 cells, the H12 cells reveal a higher background
expression of EGFP in untreated cells, and in general respond with a
smaller fold-increase thanA2 cells. Finally, heme arginate decreased
the cell viability somewhat, while SnPP with HA decreased it rela-
tively more. In parallel with the effects on EGFP expression, NAC re-
stored the cell viability in all cases.
3.7. Comparison of the effects of heme arginate with other HIV-1
reactivating agents
Finally, we have compared the stimulatory effects of HA with
the effects of several other inducers of HIV-1 reactivation during
a 48 h experiment. As shown in Fig. 8A, even 5 ll of HA/ml did
not stimulate reactivation of HIV-1 in ACH-2 cells, as characterized
by western blot analysis of the p24 Ag, while a 48 h treatment led
to a comparable increase in expression of p24 Ag in cells stimu-
lated with PMA only as well as with PMA and HA. Stimulation of
the cells with 10 U/ml of TNF-a led to an even higher expression
of p24 Ag, while 1 U/ml induced a relatively smaller expression
of p24 Ag. On the other hand, any concentration of phytohemag-
glutinin A tested (PHA; 0.5, 2.5; 5 lg/ml) alone or in combination
with 1 lM ionomycine did not yield a positive signal of p24 Ag
in western blot analysis (Fig. 8A and data not shown).
ELISA analysis of culture supernatants revealed similar changes
in levels of the p24 antigen as the western blot analysis (Fig. 8B).
However, it is obvious that the overall release of p24 by ACH-2
cells stimulated with PMA for 48 h was stronger than by ACH-2
cells stimulated with PMA and HA for the same time period. This
effect is possibly due to the death of the PMA- and HA-stimulated
cells or to the inhibitory effects of CO and bilirubin on HIV-1 reac-
tivation as discussed below.
The same stimulatory agents were also used for treatment of A2
and H12 cells for 48 h. As shown in Fig. 8C, expression of EGFP was
stimulated with HA alone weakly in both cells, very strongly with
PMA and even more strongly with PMA and HA. The stimulation
with 10 U/ml of TNF-a or 0.5–1 lg/ml PHA was comparable to
the effect of PMA, while the stimulation with 1 U/ml TNF-a
induced a relatively weaker expression of EGFP. It can be observed
that the effect of 1 U/ml TNF-a was comparable to the effect of HA
(2.5 ll/ml) in H12 cells, while it was stronger in A2 cells.
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Fig. 7. (A) Expression of heme oxygenase-1 in A2 and H12 cells. 0.5  106/ml of Jurkat cell clones A2 and H12 latently infected with a ‘‘mini-virus’’ containing the HIV-1 LTR-
Tat-IRES-EGFP-LTR were treated with increasing concentrations of HA for 48 h. The cells were collected, lysed in Laemmli reducing sample buffer, and resolved by SDS–PAGE.
Levels of HO-1 and b-actin were characterized by western blot analysis and chemiluminescence, using a rabbit polyclonal antibody against HO-1 and a rabbit polyclonal
antibody against b-actin, respectively. (B) N-acetyl cysteine prevents reactivation of HIV-1 ‘mini-virus’ and expression of EGFP. 0.5  106/ml of A2 and H12 cells were pre-
treated with N-acetyl cysteine (NAC; ﬁnal concentrations 5 and 10 mM) for 4 h and treated with 2.5 ll/ml of HA in the presence or absence of PMA (ﬁnal concentration 0.5 ng/
ml) for 48 h. Levels of EGFP and b-actin were characterized by western blot analysis and chemiluminescence, using a rabbit polyclonal antibody against EGFP and a rabbit
polyclonal antibody against b-actin, respectively. The levels of EGFP expressed in the absence of HA were visible only in longer exposures. Representative results of two
independent experiments. (C) Effect of SnPP on reactivation of HIV-1 ‘mini-virus’ and expression of EGFP. 0.5  106/ml of A2 and H12 cells were pre-treated with SnPP (ﬁnal
concentration 6.25 lM) for 30–45 min and treated with 2.5 ll/ml of HA in the presence or absence of PMA (ﬁnal concentration 0.5 ng/ml) for 48 h. Levels of EGFP and b-actin
were characterized by western blot analysis and chemiluminescence, using a rabbit polyclonal antibody against EGFP and a rabbit polyclonal antibody against b-actin,
respectively. Representative results of two independent experiments. (D) Flow cytometric analysis of EGFP expression. 0.1  106/200 ll of A2 and H12 cells were pre-treated
with N-acetyl cysteine (NAC; ﬁnal concentrations 5 mM) for 4 h, then with SnPP (ﬁnal concentration 6.25 lM) for 30–45 min, and treated with 1.25 or 2.5 ll/ml of HA in the
presence or absence of PMA (ﬁnal concentration 0.5 ng/ml) for 48 h. The cells were analyzed by ﬂow cytometry in FL1. The graphs show a quantiﬁcation of EGFP expression
calculated as the arithmetic mean of green ﬂuorescence of green cell population  percentage of all EGFP-positive cells. ⁄Increase in EGFP expression is statistically signiﬁcant
when compared to HA 0 in each treatment (p < 0.05). , Increase in EGFP expression in the presence of SnPP is statistically signiﬁcant when compared to the same treatment
without SnPP (p < 0.05). §Decrease in EGFP expression in the presence of NAC is statistically signiﬁcant when compared to the same treatment without NAC (p < 0.05).
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Fig. 8. Effects of TNF-a and phytohemagglutinin. (A and B) ACH-2 cells. 0.5  106/ml of ACH-2 cells harboring an integrated HIV-1 provirus were treated with 5 ll/ml of HA,
PMA (ﬁnal concentration 0.5 ng/ml), HA and PMA, TNF-a (ﬁnal concentration 1 and 10 U/ml) or phytohemagglutinin (PHA; ﬁnal concentration 0.5 and 1 lg/ml). 48 h after the
treatment, cells were collected and used for further analysis. (A) p24 antigen in the cells. The cells were lysed in Laemmli reducing sample buffer, and resolved by SDS–PAGE.
Levels of p24, p55 and b-actin were characterized by western blot analysis and chemiluminescence, using a mouse monoclonal antibody ND-1 against p24 and a rabbit
polyclonal antibody against b-actin, respectively. (B) p24 antigen in culture supernatant. Levels of p24 antigen in culture supernatants were determined by ELISA. Results of
two independent experiments ±SD. (C and D) A2 and H12 cells. 0.5  106/ml (C) or 0.1  106/200 ll (D) of A2 and H12 cells were treated with 1.25 ll/ml (D) or 2.5 ll/ml (C–E)
of HA, PMA (ﬁnal concentration 0.5 ng/ml), HA and PMA, PHA (ﬁnal concentration 0.5 and 1 lg/ml) or TNF-a (ﬁnal concentration 1 and 10 U/ml). 48 h after the treatment,
cells were collected and used for further analysis. (C) western blot analysis of EGFP in the cells. The cells were lysed in Laemmli reducing sample buffer, and resolved by SDS–
PAGE. Levels of EGFP and b-actin were characterized by western blot analysis and chemiluminescence, using a rabbit polyclonal antibody against EGFP and a rabbit polyclonal
antibody against b-actin, respectively. Representative results of two independent experiments. (D) Flow cytometric analysis of EGFP expression. The cells were analyzed by
ﬂow cytometry in FL1. The graphs show a quantiﬁcation of EGFP expression calculated as the arithmetic mean of green ﬂuorescence of green cell population  percentage of
all EGFP-positive cells. ⁄Increase in EGFP expression is statistically signiﬁcant when compared to HA 0 in each treatment (p < 0.05). , Increase in EGFP expression in the
presence of the stimulatory agent is statistically signiﬁcant when compared to the same concentration of HA without the agent (p < 0.05).
442 P. Shankaran et al. / Antiviral Research 92 (2011) 434–446The stimulatory effects of individual agents on the expression of
EGFP were also studied using ﬂow cytometry (Fig. 8D, Supplemen-
tary data Table S3). Again, these results reveal similar tendencies as
western blot analysis, but as mentioned above, H12 cells reveal a
higher background expression of EGFP in untreated cells than A2
cells, and in general respond with a smaller fold-increase than A2
cells. Based on various criteria used in this analysis, it can be
concluded that A2 cells are more responsive to TNF-a than H12
cells. When analyzing the cell viability, neither PMA nor TNF-a
alone or in combination with HA were found to decrease it. On
the other hand, PHA reduced cell viability relatively strongly.
3.8. Heme arginate does not affect expression of CD69 in A3.01 cells
In addition to the previous studies, we have explored the ability
of T-cells to get activated by PMA in the presence of HA. The A3.01cells were stimulated with PMA and expression of CD69 on the cell
surface was determined. In these assays, HA revealed no negative
effects on the T-cell activation characterized by this activation
marker at any concentration of PMA tested (1 and 10 ng/ml; data
not shown), especially not even at the lowest concentration used
throughout the experiments (0.5 ng/ml; Fig. 9). Importantly, HA
alone did not stimulate any increased expression of CD69 on the
cell surface either.
4. Discussion
In this paper, we demonstrate the overall inhibitory effects of
heme arginate on HIV-1 replication in T-cell lines that were accom-
panied by the inhibition of reverse transcription, while we show
that HA alone stimulated the reactivation of HIV-1 ‘‘mini-virus’’
and synergized with PMA or TNF-a in the reactivation of HIV-1
P. Shankaran et al. / Antiviral Research 92 (2011) 434–446 443provirus. To our knowledge, this is the ﬁrst work demonstrating
the stimulatory effect of hemin on reactivation of the latent
provirus.
Heme has been previously shown to inhibit replication of HIV-1
(Levere et al., 1991), speciﬁcally reverse transcriptase (Argyris
et al., 2001). Further, heme derivative hemin has been demon-
strated to inhibit HIV-1 growth in human PBMC-reconstituted
NOD-SCID mice and to induce a dose-dependent inhibition of
HIV-1 replication in tissue culture during a 7-day long infection
(Devadas and Dhawan, 2006). Accordingly, we showed here the
inhibitory effects of HA on HIV-1 replication and reverse transcrip-
tion in acutely infected cells, characterized by levels of p24 and re-
verse transcripts, respectively.
Devadas and Dhawan (2006) also found hemin to induce
expression of HO-1, and the inhibitory effects of hemin on HIV-1
replication could be reversed by certain concentrations of SnPP,
the inhibitor of HO-1. Based on these results, it would be possible
to conclude that the inhibition of HIV-1 growth was mediated by
the action of HO-1. We also observed here a HA-induced expres-
sion of HO-1 in ACH-2 cells, while its levels were already increased
in untreated A2 and H12 cells. However simultaneously, we ob-
served HA-induced stimulatory effects on HIV-1 provirus and
‘‘mini-virus’’ reactivation in ACH-2 and A2, H12 cells, respectively.
HA stimulated HIV-1 provirus reactivation in synergy with PMA or
TNF-a, while it acted alone and/or in synergy with the two agents
in A2 and H12 cells. Further, the effects of HA in A2 and H12 cells
were increased by the addition of SnPP, the inhibitor of HO-1, and
all the stimulatory effects could be inhibited by NAC. Thus based
on our results, it can be suggested that in the experiments of Deva-
das and Dhawan (2006), the inhibitory effects of hemin on HIV-1
replication were in fact over-ridden by the increased redox stress
due to inhibition of HO-1 by SnPP and the resulting increase in
expression of the provirus.
Heme and hemin differ in the oxidation state of iron in the two
compounds; they contain Fe2+ and Fe3+, respectively. In the organ-
ism, heme is mostly bound as a prosthetic group in various heme
proteins. In the presence of various oxidizing agents, the heme
moiety is oxidized to hemin, while the oxidized heme proteins as
well as the free hemin readily undergo reduction driven by CO,
both in biological systems and in vitro (Bickar et al., 1984). Changes
in the oxidation state of iron in heme moiety are also mediated byFig. 9. Heme arginate does not affect expression of CD69 in A3.01 cells. 0.5  106/ml o
absence of PMA (ﬁnal concentration 0.5 ng/ml). At 24 h after stimulation, the cells were co
with AlexaFluor-700 (dilution 1:50) followed by ﬂow cytometry analysis. Representativanother ubiquitously present gas signaling agent, nitric oxide
(Ascenzi et al., 2010; Kilbourn et al., 1994). It is thus impossible
to strictly separate the effects of heme and hemin as their mutual
balance is dynamically regulated. On the other hand, only heme
can serve as a substrate of HO-1. As a hydrophobic compound,
hemin inserts into plasma membranes and translocates inside
the cells. Inside the cells, the free iron is released namely by the ac-
tion of heme oxygenases, hydrogen peroxide or other non-speciﬁc
degradation (Belcher et al., 2010), leading to the generation of the
hydroxyl radical (Kruszewski, 2003) and activation of the redox-
sensitive transcription factor NF-jB (Lander et al., 1993; Pantano
et al., 2006). Heme also regulates levels and targeting of key en-
zymes involved in heme synthesis and degradation, non-speciﬁc
synthase of 5-aminolevulinic acid (ALAS1), HO-1, and of oxidative
stress response genes (Furuyama et al., 2007; Igarashi and Sun,
2006; Mense and Zhang, 2006).
In the time-course experiments presented in this paper, HA
inhibited HIV-1 replication characterized by levels of p24 Ag. In
similar time-course experiments, viability of the mock-infected
and infected cells in the presence of HA was found comparable
to the untreated mock-infected cells, while untreated infected cells
succumbed to apoptosis. A long-term culture of the cells in the
presence of HA in concentrations that inhibited HIV-1 replication
did not therefore negatively affect cell growth and viability; on
the contrary, HA protected the infected cells from dying. We can-
not, though, exclude a possibility that a selection of HA-resistant
cells could take place.
In contrast to the acutely infected cells, HA revealed stimulatory
effects on HIV-1 provirus and ‘‘mini-virus’’ reactivation in ACH-2
and A2, H12 cells, respectively. In A2 and H12 cells, HA stimulated
‘‘mini-virus’’ reactivation even by itself, but its effects were much
weaker than the effects of PMA, PHA, or TNF-a alone or in combi-
nation with HA. The overall EGFP expression as well as percentage
of EGFP-positive cells were dose-dependent in all agents. During a
48 h-incubation period, stimulatory effects of HA and TNF-a were
more or less comparable to HA and PMA in H12 cells, while A2 cells
appeared to be more responsive to TNF-a (Fig. 8D). Both cell lines
seemed to respond similarly to PHA. H12 cells revealed a higher
background ﬂuorescence of untreated cells than A2 cells, similarly
to the published data (Blazkova et al., 2009), but in general, they
responded to the individual inducers with a smaller fold-increasef A3.01 cells were treated with increasing concentrations of HA in the presence or
llected and stained with a mouse monoclonal antibody against human CD69 labeled
e results of two independent experiments performed in duplicates.
444 P. Shankaran et al. / Antiviral Research 92 (2011) 434–446than A2 cells. Perhaps, the lower responsiveness of H12 cells might
be due to a somewhat higher CpG methylation of the 50 LTR region
compared to A2 cells (Blazkova et al., 2009).
The observed effects of PMA on the HIV-1 provirus reactivation
in ACH-2 cells were biphasic, possibly due to a low concentration
of PMA used. During a 24 h-treatment, PMA stimulated the provi-
rus reactivation only weakly, while a 48 h-treatment induced a 10-
fold increase in the levels of p24 compared to a 24 h-treatment.
Apparently, PMA was inducing the provirus reactivation indirectly.
It seems to induce expression and/or activity of certain factors that
in turn mediate reactivation of the provirus. Phorbol esters mimic
the action of diacyl glycerols (DAG), activators of protein kinase C
family proteins (PKC) and of several non-PKC targets. In addition to
DAG or phorbolester, the full activation of PKC’s requires also Ca2+
and acidic phospholipids, leading to a synergistic activation of two
different ligand binding domains and to the appropriate membrane
targeting (Brose and Rosenmund, 2002; Goel et al., 2007). PKC was
also found to mediate expression of HO-1 stimulated by PMA or
LPS (Devadas et al., 2010; Naidu et al., 2008). The effects of PMA
in ACH-2 cells could be greatly potentiated with HA during a
24 h-treatment (Figs. 4 and 6). Possibly, HA could synergize with
PMA by changing levels of cytoplasmic Ca2+, membrane targeting
of PKC’s or by increasing the redox stress and changing the proper-
ties of zinc-ﬁnger-like repeats in C1 domain involved in PMA bind-
ing to its targets. Heme and PMA were independently shown to
affect also other signal transduction pathways, e.g. Ras and MAPK,
increasing chances for their synergistic action (Mense and Zhang,
2006; Sacks, 2006).
The exact mechanism of stimulation of HIV-1 reactivation by
HA remains to be established, but a mechanism involving induc-
tion and/or activity of HO-1 along with release of Fe2+, increased
redox stress and activation of the redox-sensitive transcription fac-
tor NF-jB can be suggested (Belcher et al., 2010; Devadas and Dha-
wan, 2006; Kruszewski, 2003; Lander et al., 1993; Morse et al.,
2009; Pantano et al., 2006). Our results indicate a HA-induced
expression of HO-1 in ACH-2 cells, while HO-1 was found present
already in untreated A2 and H12 cells. In all cell lines, LTR-driven
expression could be inhibited by pretreatment of the cells with
NAC, precursor of the potent anti-oxidant, GSH, suggesting that
the effect of HA involved an increased redox stress. In fact, we have
also detected increased production of free radicals by A3.01 and
Jurkat cells in the presence of HA or PMA (unpublished results).
Additionally, we have tested the effect of the inhibitor of HO-1,
SnPP, in A2 and H12 cells. While SnPP was not found to affect basal
expression of EGFP in either cell line, it strongly stimulated this
expression in the presence of HA in both A2 and H12 cells. Most
probably, EGFP expression could be stimulated by an increased re-
dox stress imposed by HA that could not be counteracted by the
anti-oxidative effects of HO-1 because of its inhibition by SnPP.
Alternatively, electron transfer between the two porphyrin species
and generation of ROS could take place. Again, the stimulatory ef-
fects of SnPP and HA on LTR-driven expression were inhibited by
NAC.
The other two products of heme oxygenases, CO and biliverdin,
further converted to bilirubin, reveal strong antioxidant and cyto-
protective properties (Morse et al., 2009). The effect of HA addition
thus can be shortly pro-oxidative and then anti-oxidative for a pro-
longed period of time. Thus, upon a massive induction of expres-
sion of HO-1 stimulated by HA and PMA in ACH-2 cells, the anti-
oxidative effects could eventually prevail, and inhibit provirus
reactivation during a longer incubation in the presence of HA, as
suggested by the results presented in Fig. 8A and B. The situation
seems to be different in A2 and H12 cells in which HO-1 was found
expressed already in untreated cells and its levels were not further
increased by any treatment; HO-1 thus could start to effectively
degrade HA immediately after its addition. Apparently, the kineticsand balance between the pro-oxidative and anti-oxidative effects
of HO-1 products might be different in these cells.
We have used A2 and H12 cells (Blazkova et al., 2009; Jordan
et al., 2003) to characterize the effects of HA on LTR-driven expres-
sion, comparing western blot analysis detecting levels of EGFP and
ﬂow cytometry detecting ﬂuorescence of EGFP. The ﬂow cytometry
results underestimate the numbers of EGFP-positive cells and/or
levels of EGFP expressed, as high levels of EGFP are cytotoxic and
dead cells loose EGFP ﬂuorescence. Nevertheless, we assessed the
overall expression of EGFP by the number of all EGFP-positive
cells  arithmetic mean of green ﬂuorescence of the green cell
population. Using this approximation, the levels of EGFP expres-
sion were found increased even by treatment with 1.25 ll/ml of
HA in most experiments, corresponding to the results of western
blot analysis. The percentage of green (EGFP-positive) cells in sam-
ples treated with 1.25 ll/ml of HA used to be lower than in un-
treated cells, while the arithmetic mean and median of green
ﬂuorescence of all green and live green cells, respectively, were al-
ways higher. In higher concentrations of HA, as well as in other
stimulatory treatments, all values were higher than in controls.
In general in A2 and H12 cells, HA alone or in combination with
other stimulatory agents increased LTR-driven EGFP expression
as well as cell death. These tendencies seemed to be similar in
ACH-2 cells. However, a long term incubation of A3.01 and Jurkat
cells with HA did not signiﬁcantly increase cell death. It is thus
possible that the cytotoxicity of HA might be further increased
due to expression of HIV or EGFP. In fact, it would be of advantage
if latently infected cells were more prone to cell death induced by
HA alone or in combinations. There might be several mechanisms
involved in cell death induced by HA: ﬁrst, a direct increase in ROS
production due to a higher availability of heme and iron; second,
an indirect cytotoxicity of HA that would further increase ROS pro-
duction and HIV reactivation; third, the resulting increase in HIV
reactivation would lead to the cell death. The excess of oxygen free
radicals induces oxidation of proteins, lipids, lipoproteins, nucleic
acids, carbohydrates and other cellular or viral targets. Thus, HA
might not only stimulate expression of the provirus, but also affect
the viability and infectivity of the released virions. A similar inhi-
bition of HIV-1 by reactive oxygen species was indeed shown in
the case of bleomycin (Georgiou et al., 2004).
Heme oxygenase has been suggested to exert various immuno-
regulatory effects on innate and adaptive immune cells, and to in-
hibit pathogenesis of several immune-mediated inﬂammatory
diseases (Soares et al., 2009). Further, analysis of HO-1 promoter
polymorphism revealed that Caucasian HIV-1-infected patients
who maintain low levels of immune activation and control HIV-1
viral loads to undetectable levels are more likely to possess a spe-
ciﬁc microsatellite (GT)n repeat and two single nucleotide poly-
morphisms in HO-1 promoter region that favor enhanced HO-1
gene expression (Seu et al., 2009).
The ability of cells to become activated remained unaffected by
HA as demonstrated by expression of the early activation marker
CD69, characterized by ﬂow cytometry. Since the activation of T-
cells constitutes an essential component of immune responses to
the virus itself as well as to other infections, we consider the ﬁnd-
ing that HA does not seem to generally decrease the activation of T-
cells as important. Moreover, HA did not induce any global activa-
tion of T-cells either; this ﬁnding is signiﬁcant as well, since a non-
speciﬁc T-cell activation and release of proinﬂammatory cytokines
should be avoided. The effect of HA thus could be compared to the
effect of 5-hydroxynaphthalene-1,4-dione, a compound recently
described to reactivate the latent provirus without cellular activa-
tion (Yang et al., 2009).
In vivo, HIV-1 infection can coincide with several conditions
that lead to acute or chronic hemolysis that could cause a similar
exposure to extracellular heme as does administration of HA. These
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dehydrogenase deﬁciencies, sickle cell anemia, thalasemia or other
hemoglobinopathies as well as various other diseases involving
hemolytic episodes or chronic hemolysis, especially malaria (Lopez
et al., 2010; Pamplona et al., 2009). It would be worthwhile to
determine a possible correlation of HIV-1/AIDS progression with
these conditions. However, the situation is complex and therapeu-
tic interventions, namely iron supplementation, could strongly af-
fect the ﬁne balance of pro-oxidative and anti-oxidative agents.
In clinics, HA is used to treat acute attacks of hepatic porphy-
rias. The mean maximum plasma levels of heme after a single dose
of HA 3 mg/kg body weight was determined as 60 lg/ml (corre-
sponds to 2.4 ll/ml of HA), with a plasma half-life of 10.8 h and
a distribution volume of 3.4 L (Tokola et al., 1986). The concentra-
tions of HA used throughout this paper are thus very close to the
levels achieved in clinics. Additionally, 24–48 h after administra-
tion of the same dose of hemin, but in the form of Panhematin,
plasma levels of HO-1 were increased 5-times, while its activity
in venous leukocytes increased 15-times (Bharucha et al., 2010).
Heme mediates a feedback inhibition of the rate-limiting enzyme
in the heme synthetic pathway, synthase of 5-aminolevulinic acid.
It also reconstitutes heme stores and function of various hemopro-
teins, namely hemoglobin, cytochrome P450, guanylate synthase,
nitric oxide synthases, tryptophan dioxygenase, catalase and per-
oxidase. However, neither the exact pathogenesis of the neurovis-
ceral symptoms in acute porphyrias, nor the precise mechanism of
action of heme arginate are understood (http://www.por-
phyria.uct.ac.za/professional/prof-haem-therapy.htm; Herrick and
McColl, 2005; Siegesmund et al., 2010). Nevertheless since HA
has been approved for human use, it can be suggested that HA
could be tested as a supplement of HAART in selected cases. For
example its administration could be suggested as an additional
measure in early stages of HIV/AIDS disease to release the virus
from the existing latent pool, while inhibiting its dissemination
to the new viral reservoirs. Since the levels of TNF-a and other
cytokines are increased and/or dysregulated in HIV/AIDS, HAmight
synergize with these cytokines in provirus reactivation also in vivo.
The suggestion of HA use in HIV/AIDS is further supported by a
case of an HIV-positive individual that was administered one infu-
sion of Normosang because of anemia. This patient then remained
p24 negative for several months (Pavel Martasek, General Faculty
Hospital in Prague, personal communication). Obviously, the use
of HA should be tested ﬁrst in animal models of retrovirus infection
to assess its therapeutic potential against retroviruses more clo-
sely. Also, the administration of Normosang can be complicated
by its adverse side effects. Vascular side effects of Normosang,
especially on hemostasis, can occur, but they are reported to be
much weaker than after administration of hematin (Panhaematin).
Additionally, since hemin decreased HIV growth in humanized
mice even when administered intraperitoneally (Devadas and Dha-
wan, 2006), it is possible that the i.p. or some other way of admin-
istration of Normosang would be also effective against HIV in
humans. Repeated administrations of HA could lead to an iron
overload. However, HIV/AIDS disease is often accompanied by
the anemia due to a chronic immune activation, altered porphyrin
metabolism caused by iron deﬁciency (Adetifa and Okomo, 2009;
Fuchs et al., 1990) as well as by treatment with antiretrovirals
(Bozzi et al., 2004; Fox et al., 1999). All these conditions would
be improved by the administration of heme, while iron overload
might not develop.
On the whole, these results suggest a possibility of an alterna-
tive approach to the management of HIV/AIDS disease. HA seems
to possess a combination of two unique properties: it can help to
reactivate the provirus from latent pools, and simultaneously pre-
vent HIV-1 dissemination into new cells and/or expansion of thelatent pool. In this way, HA could signiﬁcantly prolong the latent
stage of the disease and/or delay the depletion of CD4+ T-cells.
In conclusion, we demonstrate the inhibitory properties of
heme arginate, Normosang, on HIV-1 reverse transcription and
the overall replication on the one hand, and its stimulatory effects
on reactivation of the latent provirus on the other hand. Altogether,
the results suggest a new direction to explore in treatment of HIV/
AIDS infection.
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